Key Points
- GRAIL CEO Robert Ragusa sold 7,461 shares on March 9 at an average price of $47.89 for about $357,307, reducing his stake by ~1.15% to 642,084 shares (SEC filing).
- Multiple senior insiders trimmed holdings — President Joshua Ofman and CFO Aaron Freidin also sold shares on March 5 and March 9, reflecting a series of insider sales in early March.
- Company and stock snapshot: GRAL opened at $49.82 (down ~0.8%), market cap ~$1.94B; it reported Q4 EPS of -$2.44 (beating estimates) and $43.6M revenue, while analysts project a roughly -$15.15 EPS for the current fiscal year and the stock shows high volatility (beta 5.21).
GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) CFO Aaron Freidin sold 655 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $53.01, for a total transaction of $34,721.55. Following the sale, the chief financial officer owned 308,967 shares of the company's stock, valued at $16,378,340.67. This trade represents a 0.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Aaron Freidin also recently made the following trade(s):
- On Monday, March 9th, Aaron Freidin sold 2,492 shares of GRAIL stock. The stock was sold at an average price of $47.89, for a total value of $119,341.88.
- On Monday, March 2nd, Aaron Freidin sold 9,573 shares of GRAIL stock. The shares were sold at an average price of $50.17, for a total value of $480,277.41.
GRAIL Trading Down 0.8%
Shares of NASDAQ GRAL opened at $49.82 on Tuesday. The firm has a market cap of $1.94 billion, a P/E ratio of -4.46 and a beta of 5.21. GRAIL, Inc. has a 1-year low of $20.44 and a 1-year high of $118.84. The business's 50 day moving average is $88.14 and its 200-day moving average is $77.99.
GRAIL (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, topping the consensus estimate of ($3.33) by $0.89. The business had revenue of $43.60 million during the quarter, compared to analysts' expectations of $43.33 million. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%. Analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on GRAL. Morgan Stanley reduced their target price on shares of GRAIL from $110.00 to $60.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 24th. Canaccord Genuity Group lowered their price target on shares of GRAIL from $105.00 to $80.00 and set a "buy" rating on the stock in a research report on Friday, February 20th. Robert W. Baird set a $82.00 price objective on shares of GRAIL in a research note on Friday, February 20th. Guggenheim boosted their price objective on shares of GRAIL from $100.00 to $130.00 and gave the company a "buy" rating in a report on Monday, January 26th. Finally, TD Cowen assumed coverage on shares of GRAIL in a research report on Thursday, February 19th. They set a "hold" rating and a $114.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, GRAIL has an average rating of "Hold" and a consensus target price of $90.17.
Check Out Our Latest Stock Analysis on GRAIL
Trending Headlines about GRAIL
Here are the key news stories impacting GRAIL this week:
- Negative Sentiment: CEO Robert P. Ragusa sold 7,461 shares on March 9 at an average $47.89 (~$357,307), cutting his position by ~1.15%. SEC Filing
- Negative Sentiment: CEO Robert P. Ragusa sold 980 shares on March 5 at $53.01 (~$51,950), a ~0.15% reduction in his stake. SEC Filing
- Negative Sentiment: President Joshua J. Ofman sold 2,937 shares on March 9 at $47.89 (~$140,653), trimming his holding by ~0.67%. SEC Filing
- Negative Sentiment: President Joshua J. Ofman sold 690 shares on March 5 at $53.01 (~$36,577), a ~0.16% reduction in his stake. SEC Filing
- Negative Sentiment: CFO Aaron Freidin sold 2,492 shares on March 9 at $47.89 (~$119,342), reducing his position by ~0.81%. SEC Filing
- Negative Sentiment: CFO Aaron Freidin sold 655 shares on March 5 at $53.01 (~$34,722), a ~0.21% reduction in his holding. SEC Filing
Hedge Funds Weigh In On GRAIL
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC increased its position in shares of GRAIL by 73.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company's stock worth $200,510,000 after purchasing an additional 993,684 shares during the period. Morgan Stanley raised its stake in GRAIL by 63.8% in the fourth quarter. Morgan Stanley now owns 1,511,687 shares of the company's stock valued at $129,385,000 after purchasing an additional 588,647 shares in the last quarter. State Street Corp lifted its position in GRAIL by 38.8% during the fourth quarter. State Street Corp now owns 1,827,523 shares of the company's stock worth $156,418,000 after purchasing an additional 510,546 shares during the period. Baker BROS. Advisors LP lifted its position in GRAIL by 27.9% during the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company's stock worth $178,484,000 after purchasing an additional 455,208 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new stake in GRAIL during the fourth quarter worth about $37,874,000.
About GRAIL
(
Get Free Report)
GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.
Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
